Area of research
Biomedical Engineering · Pulmonary and Respiratory Medicine
Research interest
Research interests include Nanoplatforms for cancer theranostics, Photodynamic Therapy Research Studies, Immunotherapy and Immune Responses, and Nanoparticle-Based Drug Delivery.
Cuproptosis amplifier of copper-telaglenastat coordinate to trigger cell ferroptosis for synergistic breast cancer suppression
Lymph node targeting nanomedicines for tumor immunotherapy
Golgi Apparatus-Targeting Immunostimulant for Synergistic Activation of Antitumor Immunity via Pyroptosis Induction and PD-L1 Degradation.
Chlorin e6 and Regorafenib Assemblies to Boost Photodynamic Immunotherapy through PD-L1 Downregulation and Tumor-Associated Macrophage Reprogramming.
Stearic acid-modified PSMA-targeting peptide-drug conjugate for long-acting prostate cancer therapy.
Metal-drug coordinated nanozymes for ROS scavenging and Kupffer cell polarization to alleviate drug-induced liver injury
Plasma Membrane Targeted Photodynamic Nanoagonist to Potentiate Immune Checkpoint Blockade Therapy by Initiating Tumor Cell Pyroptosis and Depleting Infiltrating B Cells.
Chemotherapeutics-enabled apoptosis-pyroptosis switch to trigger adaptive and innate immunity for metastatic breast cancer immunotherapy
Self‐Promoting Targeted Delivery of Epigenetic Immunostimulants to Activate Breast Cancer Immunity via HDACs Downregulation and PD‐L1 Upregulation
Endoplasmic reticulum targeting photodynamic oxidizer to boost anti-tumor immunity by intensifying immunogenic cell death in conjunction with IDO1 inhibition
Phosphatidylserine decorated inhalable immunostimulants to eradicate pulmonary metastasis through alveolar macrophage polarization and phagocytosis restoration in situ
Carrier-adjuvanted immunostimulator to boost photodynamic immunotherapy by downregulating PD-L1 and impairing ATP hydrolysis
Macrophage and mitochondria targeted nanoplatform to deplete and polarize M1-like macrophages for rheumatoid arthritis treatment
A CXCR4-targeted immunomodulatory nanomedicine for photodynamic amplified immune checkpoint blockade therapy against breast cancer
A CXCR4-targeted immunomodulatory nanomedicine for photodynamic amplified immune checkpoint blockade therapy against breast cancer.
Chimeric Peptide-Engineered Polyprodrug Enhances Cytotoxic T Cell Response by Inducing Immunogenic Cell Death and Upregulating Major Histocompatibility Complex Class I.
Anti-Triggering Receptor Expressed on Myeloid Cells 2-Conjugated Nanovesicles Loaded Vadimezan Reprogram Tumor-Associated Macrophages to Combat Recurrent Lung Cancer
Self-Promoting Targeted Delivery of Epigenetic Immunostimulants to Activate Breast Cancer Immunity via HDACs Downregulation and PD-L1 Upregulation.
Fibroblast‐Activation Protein Targeted Immunostimulant to Provoke Colorectal Cancer Immunity Through Photodynamic Depleting and Chemotherapeutic Silencing of Cancer Associated Fibroblasts
A stimuli-responsive immunostimulant to activate chemo-immunotherapeutic effects by inducing DNA damage and STING activation.
Chimeric Peptide Functionalized Immunostimulant to Orchestrate Photodynamic Immunotherapeutic Effect by PD-L1 Deglycosylation and CD47 Inhibition.
Fibroblast‐Activation Protein Targeted Immunostimulant to Provoke Colorectal Cancer Immunity Through Photodynamic Depleting and Chemotherapeutic Silencing of Cancer Associated Fibroblasts
Metal-phenolic network crosslinked nanogel with prolonged biofilm retention for dihydroartemisinin/NIR synergistically enhanced chemodynamic therapy.
A Ferroptosis Amplification Loop Induced by Compensatory Nanomedicine Enhances Breast Cancer Immunotherapy
Feedback-Amplified Drug Delivery of αPD-L1-Modified Lipoplatin for Chronological Synergy in NSCLC through PD-L1 Upregulation
Self-promoted tumor-targeting nanomedicine activates STING-driven antitumor immunity <i>via</i> photodynamic DNA damage and PARP inhibition.
Overexpressing mannose-binding Lectin (NTL) protein affects sugarcane physiological status and increase its resistance to aphids (Ceratovacuna langigera)
Feedback-Amplified Drug Delivery of αPD-L1-Modified Lipoplatin for Chronological Synergy in NSCLC through PD-L1 Upregulation.
Cu<sup>2+</sup>‐Coordinated NLG919: A Drug Delivery Nanoplatform to Activate Antitumor Immunity via Inducing Immunogenic Cell Death and Inhibiting Indoleamine 2,3‐Dioxygenase‐1
Recent Progress of Epigenetic Reprogramming Biomedicine to Activate Immunotherapeutic Antitumor Effects